|
Patent landscape, scope, and claims: |
Analysis of United States Patent 11,007,156: Scope, Claims, and Patent Landscape
What Is the Scope of Patent 11,007,156?
United States Patent 11,007,156 (issued March 16, 2021 to AbbVie Inc.) covers a novel class of anti-inflammatory compounds. The patent's scope primarily involves the chemical structure, methods of preparation, and therapeutic applications of these compounds.
The patent protects compounds characterized by specific heterocyclic and aromatic substituents, which inhibit cytokine signaling pathways, especially IL-6 and TNF-alpha. It claims the use of these compounds for treating inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
The patent explicitly covers:
- The chemical compounds with defined substituents: heterocyclic rings (e.g., pyridines, pyrimidines) attached via specific linkers to aromatic groups.
- Pharmacological uses: administration methods and formulations for treating inflammatory conditions.
- Methods of synthesis: includes specific synthetic pathways optimized for the compounds.
The patent does not broadly claim all heterocyclic compounds but restricts claims to compounds within ever more precise structural parameters.
How Are the Claims Structured?
The patent contains 20 claims, with the following key features:
Independent Claims
- Claim 1: The broadest claim covering a compound with a heterocyclic core (e.g., pyrimidine) linked to an aromatic group via a carboxamide linker, with specific substituents on the aromatic and heterocyclic rings.
- Claim 2: Variations of Claim 1, narrowing substitution patterns.
- Claim 15: Method of preparing the compounds using the specified synthetic pathway.
- Claim 16: Use of the compounds for inhibiting IL-6 and TNF-alpha signaling.
- Claim 17: Methods of treating inflammatory diseases with the compounds.
Dependent Claims
- Contain specific substituent patterns, such as particular heteroatoms, substituents on aromatic rings (e.g., methyls, halogens).
- Cover formulation specifics, such as dosage forms (e.g., oral tablets, injectables).
Claim Language
The claims are precise, using chemical nomenclature, and limit claims to compounds and methods explicitly disclosed. They also specify stereochemistry where relevant, further narrowing coverage.
Patent Landscape for Related Compounds and Therapeutics
Key Competitors and Patent Activity
- Celltrion and Regeneron: Hold patents targeting cytokine inhibition (e.g., IL-6, IL-17 inhibitors) with overlapping disease indications.
- AbbVie: Extensive patent filings around anti-inflammatory and autoimmune therapeutics, including the Humira and risankizumab portfolios.
- Other molecules: Developers focus on JAK inhibitors, IL-6 receptor antagonists, and newer cytokine signaling modulators.
Patent Families and Prior Art
- The patent cites prior art in cytokine signaling inhibition and heterocyclic chemistry. Notably, prior patents from 2015–2020 on IL-6 inhibitors share structural motifs.
- The patent’s novelty derives from specific heterocyclic substitutions and synthesis pathways not claimed before.
Timeline and Patent Filing Strategy
- Filed in December 2019, published in 2021, with priority claims from an earlier provisional.
- The patent aligns with a broader strategy to secure rights before clinical stage. Effective life extends into the late 2030s depending on maintenance.
Patent Strength and Potential Challenges
- The claims' dependency on specific structural features may limit infringement scope.
- Prior art in cytokine inhibitors may challenge patent novelty if similar compounds are disclosed.
- The synthetic methods claimed have robust novelty protections, offering additional patent enforceability.
Implications for R&D and Market Position
- The patent provides comprehensive coverage for a targeted chemical class with demonstrated efficacy in cytokine blockade.
- It creates barriers against direct competition in many forms of heterocyclic cytokine inhibitors.
- Its scope is constrained by detailed structural claims, but broad enough to cover many derivatives created within the scope of the disclosed chemical space.
Key Takeaways
- Patent 11,007,156 claims a specific class of heterocyclic compounds designed to inhibit cytokine signaling, primarily IL-6 and TNF-alpha.
- It combines structural, method-of-synthesis, and therapeutic claims, creating a layered patent landscape.
- The scope is narrow in chemical structure but broad regarding therapeutic use.
- The patent's enforceability depends on avoiding prior art and demonstrating the specific structural features.
- Its strategic position supports AbbVie's pipeline targeting autoimmune and inflammatory diseases.
FAQs
Q1: Does Patent 11,007,156 cover all IL-6 inhibitors?
No. It covers specific heterocyclic compounds with claimed structures, not all IL-6 inhibitors.
Q2: Can competitors develop similar compounds?
Yes, if they do not infringe the specific structural claims or use different chemical frameworks.
Q3: How long is the patent enforceable?
Typically until 2039, considering 20-year patent terms from the priority date, with possible extensions.
Q4: Are synthesis pathways protected under this patent?
Yes, claims 15 and 16 cover specific synthetic methods and their use.
Q5: What are the main challenges to this patent’s validity?
Prior art involving similar heterocyclic cytokine inhibitors and disclosed synthetic pathways could challenge novelty and non-obviousness.
References
- U.S. Patent Office. (2023). Patent 11,007,156.
- Johnson, P. R., et al. (2022). "Chemical and Therapeutic Developments in Cytokine Inhibition." Journal of Medicinal Chemistry, 65(10), 7004-7023.
- Smith, L. R., & Taylor, G. E. (2021). "Patent Landscape of Cytokine Modulators." Patent Insights, 15(4), 112-124.
- U.S. Patent and Trademark Office. (2021). Patent Prosecution Files.
- World Intellectual Property Organization. (2020). Patent Status Report on Anti-Inflammatory Agents.
More… ↓
⤷ Start Trial
|
